Immunomedics Reports IMMU-130 is Active in Patients With Irinotecan-Refractory Colorectal Cancer

Immunomedics Reports IMMU-130 is Active in Patients With Irinotecan-Refractory
Colorectal Cancer

CHICAGO, June 2, 2014 (GLOBE NEWSWIRE) -- Immunomedics, Inc., (Nasdaq:IMMU)
today reported 10 of 14 patients (71%) with metastatic colorectal cancer
(mCRC) responded to IMMU-130, the Company's novel investigational
antibody-drug conjugate (ADC) that comprises an anti-CEACAM5 antibody and
SN-38, the active metabolite of irinotecan.

Commenting on this finding, Cynthia L. Sullivan, President and Chief Executive
Officer said, "We believe the high response rate from these heavily pretreated
patients who had failed prior irinotecan treatment suggests that IMMU-130 was
able to deliver SN-38 to the tumor at an amount high enough to overcome the
tumor's resistance to this class of drugs."

A total of 21 patients with mCRC have been enrolled into the multicenter Phase
I trial to receive IMMU-130 either once or twice weekly for 2 weeks in 3-week
cycles. Treatment responses from 14 patients with at least one computed
tomography (CT) assessment were presented at the 2014 Annual Meeting of the
American Society of Clinical Oncology in Chicago, IL.

The 14 CT-assessable patients had a median of 4.5 prior therapies (range 1 -
11), one of which must have been an irinotecan-containing regimen. Median time
to progression for all 14 patients was at least 15.0 weeks (range 5.9 - >41.1
weeks), with 1 patient showing an 84% tumor shrinkage and an ongoing duration
of partial response of more than 7 months. This patient continues to receive
treatment and has received a total of 42 doses of the ADC thus far. However,
to date, retreated patients have not shown an immune response to the ADC.

The frequent dosing of IMMU-130 appears to be well tolerated by patients, with
transient and reversible neutropenia, and manageable diarrhea the major side
effects, which were mild and irregular.

"In addition to CRC, CEACAM5 expression is also elevated in breast and lung
cancers, as well as other tumors, making them potential targets for IMMU-130,
which has shown in this trial to have a high therapeutic index," Ms. Sullivan

About Immunomedics

Immunomedics is a clinical-stage biopharmaceutical company developing
monoclonal antibody-based products for the targeted treatment of cancer,
autoimmune disorders and other serious diseases. Immunomedics' advanced
proprietary technologies allow the Company to create humanized antibodies that
can be used either alone in unlabeled or "naked" form, or conjugated with
radioactive isotopes, chemotherapeutics, cytokines or toxins. Using these
technologies, Immunomedics has built a pipeline of nine clinical-stage product
candidates. Immunomedics has an ongoing collaboration with UCB, S.A. (UCB),
who has worldwide rights in non-cancer indications to Immunomedics' Phase III
product candidate, epratuzumab. UCB expects Phase III data in systemic lupus
erythematosus (SLE) in the first quarter of 2015. Immunomedics is exploring
epratuzumab in oncology in collaboration with outside cancer study groups.
Immunomedics' most advanced wholly owned candidate is ^90Y-clivatuzumab
tetraxetan, which is in an ongoing Phase III registration trial in patients
with pancreatic cancer. Immunomedics' portfolio of wholly owned product
candidates also includes antibody-drug conjugates (ADCs) that are designed to
deliver a specific payload of a chemotherapeutic directly to the tumor while
reducing overall toxicity effects that typically occur when these
chemotherapeutic agents are dosed alone. Immunomedics' most advanced ADCs are
IMMU-132 and IMMU-130, which are in Phase I/II trials for a number of solid
tumors and metastatic colorectal cancer (mCRC), respectively. Immunomedics
also has a number of other product candidates that target solid tumors and
hematologic malignancies, as well as other diseases, in various stages of
clinical and pre-clinical development. These include bispecific antibodies
which have application as T-cell redirecting immunotherapies targeting cancers
and infectious diseases as well as next-generation therapies in cancer and
autoimmune disease. Immunomedics creates these bispecific antibodies using its
patented DOCK-AND-LOCK™ (DNL™) protein conjugation technology. The Company
believes that its portfolio of intellectual property, which includes
approximately 248 active patents in the United States and more than 400
foreign patents, protects its product candidates and technologies.
Immunomedics' strength in intellectual property has resulted in the top-4
ranking in the January 2014 Patent Board scorecard in the Biotechnology
industry. For additional information on the Company, please visit its website
at The information on its website does not, however,
form a part of this press release.

This release, in addition to historical information, may contain
forward-looking statements made pursuant to the Private Securities Litigation
Reform Act of 1995. Such statements, including statements regarding clinical
trials (including the funding therefor, outcomes, timing or associated costs),
out-licensing arrangements (including the timing and amount of contingent
payments), forecasts of future operating results, potential collaborations,
and capital raising activities, involve significant risks and uncertainties
and actual results could differ materially from those expressed or implied
herein. Factors that could cause such differences include, but are not limited
to, new product development (including clinical trials outcome and regulatory
requirements/actions), our dependence on UCB for the further development of
epratuzumab for non-cancer indications, risks associated with the outcome of
pending litigation, competitive risks to marketed products and availability of
required financing and other sources of funds on acceptable terms, if at all,
as well as the risks discussed in the Company's filings with the Securities
and Exchange Commission. The Company is not under any obligation, and the
Company expressly disclaims any obligation, to update or alter any
forward-looking statements, whether as a result of new information, future
events or otherwise.

CONTACT: For More Information:
         Dr. Chau Cheng
         Senior Director, Investor Relations & Grant Management
         (973) 605-8200, extension 123
Press spacebar to pause and continue. Press esc to stop.